Article
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Cancer - 1 Jun 2006
Booton Richard, Ward Tim, Heighway Jim, Taylor Pat, Power Fiona, Ashcroft Linda, Morris Julie, Thatcher Nicholas
Abstract excerpt
BACKGROUND: The treatment of lung cancer has reached a therapeutic plateau. Several mechanisms of platinum resistance have been described, including the removal of platinum-DNA adduct by nucleotide excision repair (NER). Polymorphisms within the Xeroderma pigmentosum Group D protein (XPD), a member of the NER pathway, are associated with alterations in enzyme activity and may change sensitivity to platinum-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
